Head and Neck Cancer

Scottsdale, AZ—Definitive chemoradiation with single-agent outpatient chemotherapy for head and neck cancer led to disease control and survival equivalent to that of inpatient multi-agent therapy, at an annualized savings of almost $650,000, according to results of a small randomized trial presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Scottsdale, AZ—The addition of chemotherapy to irradiation proved superior to accelerated radiotherapy without systemic therapy in a randomized trial of patients with advanced head and neck cancer.

Berlin, Germany—Although little is known about the prevalence of lymphedema in patients with head and neck cancer, a series of studies showed that 75% of patients with head and neck cancer have problematic lymphedema internally and externally.

Toronto, Canada—A Healthcare Qual­ity Calculator (HQCal) created by re­searchers at Vanderbilt University School of Medicine, Nashville, TN, allows decision makers to determine which investments are the most cost-efficient for improving quality of care, according to a new study presented at the 2012 International Conference on Head and Neck Cancer.

Toronto, Canada—The popularity of intensity-modulated radiotherapy (IMRT) for head and neck cancer has climbed rapidly in recent years. How­ever, the extra cost associated with this treatment modality may not equate with improved value, according to researchers from the University of California at Los Angeles (UCLA), who presented their analysis at the 2012 International Conference on Head and Neck Cancer.

Results 1 - 5 of 5
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology